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Abstract
Background Myofibrillar myopathies (MFM) are a subgroup of protein aggregate myopathies (PAM) characterized by a com-
mon histological picture of myofibrillar dissolution, Z-disk disintegration, and accumulation of degradation products into
inclusions. Mutations in genes encoding components of the Z-disk or Z-disk-associated proteins occur in some patients whereas
in most of the cases, the causative gene defect is still unknown. We aimed to search for pathogenic mutations in genes not
previously associated with MFM phenotype.
Methods We performed whole-exome sequencing in four patients from three unrelated families who were diagnosed with PAM
without aberrations in causative genes for MFM.
Results In the first patient and her affected daughter, we identified a heterozygous p.(Arg89Cys) missense mutation in LMNA
gene which has not been linked with PAM pathology before. In the second patient, a heterozygous p.(Asn4807Phe) mutation in
RYR1 not previously described in PAM represents a novel, candidate gene with a possible causative role in the disease. Finally, in
the third patient and his symptomatic daughter, we found a previously reported heterozygous p.(Cys30071Arg) mutation in TTN
gene that was clinically associated with cardiac involvement.
Conclusions Our study identifies a new genetic background in PAM pathology and expands the clinical phenotype of known
pathogenic mutations.
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Introduction
Myofibrillar myopathies (MFM) are a group of protein aggregate
myopathies (PAM) sharing the histological features of Z-disk
dissolution, myofibrillar degeneration, and accumulation of deg-
radation products into protein aggregates [1–4]. The clinical
spectrum is wide and consists mainly in progressive muscle
weakness of upper and/or lower limbs; limb-girdle and scapulo-
peroneal phenotypes can be observed as well as involvement of
hand, facial, pharyngeal, and respiratory muscles [1–4].
Cardiomyopathy, peripheral neuropathy, and cataract are fre-
quent associated conditions [1–4]. The diagnosis is established
bymuscle biopsy which shows asmainmorphological hallmark,
abnormal fibers containing amorphous material of irregular
shape and size positive to several proteins including αB-
crystallin, desmin, and myotilin [1–3]. MFM are usually trans-
mitted as an autosomal dominant trait; however, X-linked, auto-
somal recessive and sporadic cases have been described [1–4].
Causative mutations have been identified in a minority of pa-
tients in one of the following genes: desmin (DES), αB-
crystallin (CRYAB), myotilin (MYOT), Z-band alternatively
spliced PDZ-containing protein (LBD3/ZASP), Bcl2-associated
athanogene-3 (BAG3), and filamin C (FLNC) [1–5]. Recent mu-
tations in FHL1, TTN, DNAJB6, PLEC, ACTA1, HSPB8,
LMNA, KY, PYROXD1, and SQSTM1 have also been reported
in patients featuring MFM pathology highlighting the variability
and complexity of these muscular disorders [5].
We performed whole-exome sequencing (WES) in four
patients with PAM from three unrelated families in whom
classical genetic approach had failed to identify a causative
mutation in one of the known MFM causing genes.
Materials and methods
Patients
We studied three unrelated families in which the probands di-
agnosed with PAM had negative results by gene testing for
MFM including DES, CRYAB, MYOT, LBD3/ZASP, BAG3,
and FLNC (Fig. 1). The diagnosis of MFM was established
according to the clinical and morphological criteria provided
by Schröder and Schoser [2]. Muscle biopsies were performed
for diagnostic purpose. All patients provided written informed
consent to the study, which was approved by our local Ethics
Committee and conducted in accordance with the ethical guide-
lines of the Declaration of Helsinki.
Immunohistochemical studies
Immunohistochemistry was performed on 8-μm-thick muscle
sections with antibodies to desmin, αB-crystallin, myotilin,
and lamin A/C. The react ions were revealed by
immunofluorescence methods as previously described [4].
Hoechst 33258 staining was used to depict cell nuclei.
Genetic investigations
Whole-exome sequencing (WES) was performed on four af-
fected members of three families (Family 1:II-2 and III-2,
Family 2:II-1, and Family 3:II-2). Genomic DNA libraries
were prepared using the KAPA HTP library preparation kit,
multiplexed to 8-plex pools prior to the SeqCap EZ Exome
v2.0 capture (Roche NimbleGen) and sequenced on the
Illumina HiSeq platform (2 × 100-bp reads). Mean coverage
in range 26.07–34.39x and ge10 in range 48.9–51.1% were
achieved. One sample was captured using MedExome probes
(Roche NimbleGen) and sequenced to reach 93.87x mean
coverage and 96.9% ge20. All steps were carried out accord-
ing to original protocols.
Variant discovery included the following steps: quality
control of raw FASTQ, adapter trimming, and low-quality
reads removal using Trimmomatic, read mapping to hg19 ge-
nome using BWA, duplication removal, local realignment,
and quality recalibration using GATK and Picard, and variant
calling using UnifiedGenotyper, HaplotypeCaller, and
FreeBayes [6–9].
Variants were filtered using public (NHLBI ESP,
gnomAD) and internal databases in order to remove common
genetic variation [10, 11]. CADD, PolyPhen2, SIFT,
FATHMM, andMutationTaster were used to identify possible
protein-damaging variants [12–16]. Variants were classified
using ClinVar and VarSome databases [17, 18].
Selected variants were detected independently using the
Sanger sequencing using BigDye Chemistry (Applied
Biosystems, Foster City, CA) on Genetic Analyzer 3500
(Applied Biosystems).
Results
Clinical, laboratory, and pathology data
Family 1
A 64-year-old Caucasian woman (II-2) reported a 6-month his-
tory of progressive muscle weakness with difficulty in climbing
stairs and lifting weights. At age 33 years, an arrhythmogenic
cardiomyopathy was diagnosed, and 14 years later, heart trans-
plantation was performed. Past medical history was remarkable
for type 2 diabetes mellitus, hypothyroidism, chronic kidney
disease, and right radical nephrectomy for renal oncocytoma.
At the time of clinical evaluation, she was able to walk for short
distances and had moderate to marked weakness of proximal
four-limb muscles with a mild involvement of distal muscles of
the upper limbs. Deep tendon reflexes, sensation, and cerebellar
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examination were normal. The patient did not have respiratory
symptoms and facial muscles were spared. Serum creatine kinase
(sCK) was within the reference range while electromyography
(EMG) showed diffuse myopathic changes. An open biopsy of
left deltoid muscle showed increased fiber size variation, rare
rimmed vacuoles, slight endomysial fibrosis, rare fibers contain-
ing amorphous material, and several fibers with patchy areas of
reduced or increased staining of oxidative enzymes (Fig. S1).
Abnormal muscle fibers had an ectopic accumulation of αB-
crystallin, desmin, and myotilin by immunohistochemistry
(Fig. 2). The patient died at age 67 years from unrelated causes.
Her father (I-1) and paternal grandmother had similar heart
disease. Her son (III-1) had died at the age of 20 due to cardio-
myopathy. Her 41-year-old daughter (III-2) presented from the
age of 18 years an arrhythmogenic cardiomyopathy for which
she first necessitated pacemaker implantation and then radiofre-
quency ablation for atrial flutter. From the age of 36, she devel-
opedmild proximal lower limbsmuscleweaknesswithwaddling
gait. The proband had one healthy sister (II-3) and two brothers,
one of which, aged 73 years (II-5), presented severe weakness of
proximal limb muscles started at the age of 69 years. He also
suffered from atrial fibrillation, diabetes mellitus, and arterial
hypertension, which give a clinically different picture as com-
pared to the affected patient and her daughter.
Family 2
A 42-year-old Caucasian man (II-1) was referred for diffuse
myalgia both at rest and exercise-related and gait disturbances
started 1 month earlier. Past medical history was notable for
atrial fibrillation requiring ablation. On neurological examina-
tion, he presented difficulty in walking on toes and heels with
mild weakness and wasting of tibialis anterior muscles and
bilateral pes cavus. Strength was normal in the remaining
muscle groups. Ankle jerks were absent, while sensory, cere-
bellar, and cranial nerve examination were normal. sCK level
was in the normal range and EMG recorded a mixed pattern
with both neuropathic and myopathic changes in distal lower
limb muscles. The patient underwent a biopsy of left tibialis
anterior muscle that showed increased variation of fiber size
with atrophic and hypertrophic fibers, fiber splitting, rare sar-
coplasmic masses and ring fibers, slight increase of
endomysial connective tissue, and fibers containing amor-
phous material that was eosinophilic by hematoxylin and eo-
sin (H&E) and dark blue by modified Gomori trichrome (GT)
(Fig. 3 and S2). A single fiber harbored cytoplasmic bodies.
Immunohistochemical studies demonstrated the focal accu-
mulation of desmin, αB-crystallin, and myotilin within abnor-
mal muscle fibers (Fig. 3). Family history was unremarkable.
The patient had one brother who was asymptomatic (II-2).
Family 3
A 45-year-old Caucasian man (II-1) reported a 1-year history
of progressive muscle weakness of the lower limbs with dif-
ficulty in climbing stairs. Shortly, he developed severe dys-
pnea requiring hospitalization in the intensive care unit for
acute hypercapnic respiratory failure that necessitated first en-
dotracheal intubation and invasive mechanical ventilation
then nocturnal non-invasive ventilation. His past medical
Fig. 1 Pedigrees of the three
families. Arrows indicate the
proband in each pedigree. Solid
black symbols denote affected
family members. Gray solid
symbol represents patient affected
by myopathy but not carrying
p.(Arg89Cys) LMNA mutation
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history was significant for type 2 diabetes mellitus and blood
hypertension. On physical examination, the patient had a wad-
dling and steppage gait and could not lift his arms above the
head. There was moderate symmetric muscle weakness of
shoulder abductors, hip flexors, hip abductors, and foot exten-
sors, associated to mild proximal muscle wasting. Sensory,
cerebellar, and cranial nerve examination and deep tendon
reflexes were normal. The sCK level was within the reference
range and the nerve conduction study revealed a mild sensory-
motor polyneuropathy without myopathic changes at needle
EMG. Cardiac examination by electrocardiography and ultra-
sound documented sinus tachycardia. A biopsy of vastus
lateralis muscle showed slight fiber size variation, multiple
cytoplasmatic bodies, many fibers harboring amorphous ma-
terial, and several fibers with “rubbed-out” regions by NADH
stain (Fig. 4 and S3). These abnormal fiber areas were strongly
Fig. 2 Muscle biopsy findings
from proband of Family 1. H&E
stained section (a) shows a
muscle fiber containing a small
focus of amorphous material,
which strongly immunoreacts for
αB-crystallin (b), desmin (c), and
myotilin (d). Images were ob-
tained with obj × 20
Fig. 3 Muscle biopsy findings from proband of Family 2. H&E (a) and
GT (b) show a muscle fiber harboring amorphous material. NADH
staining (c) shows a fiber with focal decrease activity. Muscle fiber with
strong immunoreactivity for αB-crystallin (d), desmin (e), and myotilin
(f). Images were obtained with obj × 20
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immunoreactive for antibodies to desmin, αB-crystallin, and
myotilin. The patient died suddenly at the age of 55 years.
His sister (II-3) was examined at the age of 40 years be-
cause of difficulty in walking and raising from a chair proba-
bly started in young adulthood. On neurological examination,
she had a waddling and steppage gait with mild trunk
anteroflexion and scoliosis. She had a moderate weakness of
hip flexors and severe weakness of foot extensors associated
to proximal lower limb muscle wasting. At the upper limbs, a
mild proximal weakness, especially of elbow extensors, and
left scapular winging were observed, without significant mus-
cle atrophy. No sensory, cerebellar, or cranial nerves involve-
ment was present. Triceps and ankle deep tendon reflexes
were absent. The patient noticed shortness of breath approxi-
mately from the age of 48 years when she started assisted
ventilator at night. At the age of 54 years, she presented re-
current bouts of drug-refractory supraventricular tachycardia
requiring ablation. Clinical examination at the age of 57 years
showed severe weakness in almost all the muscles at four
limbs. The sCK level was 2-fold above control value and
EMG recorded a diffuse myopathic pattern. A needle biopsy
of vastus lateralis muscle performed at the age of 41 years
showed dystrophic features with marked fiber size variation,
central nuclei, fiber splittings, few necrotic fibers, and
perimysial and endomysial fibrosis. In addition, many fibers
with “rubbed-out” areas were seen in NADH-stained sections.
Family history was relevant for gait difficulties in their pater-
nal aunt.
Genetic investigations
The whole-exome data analysis identified candidate causative
variants in all three families (Fig. 5 and Table 1) as well as
several variants of unknown significance (VUS) (Table S1
and S2). Candidate causative variants in LMNA (Family 1),
RYR1 (Family 2), and TTN (Family 3) genes have null fre-
quencies in gnomAD database as well as in our internal
database. The p.(Arg89Cys) variant in LMNA gene is classi-
fied as “likely pathogenic” by the Varsome database accord-
ing to the ACMG guidelines [19], together with the neighbor-
ing chr1:156084975-G>T (p.Arg89Leu) variant, which is also
classified as pathogenic in the ClinVar database. Both LMNA
variants have been described before in individuals with car-
diomyopathy [20–22]. The RYR1 p.(Asn4807Phe) variant is
caused by a dinucleotide substitution. Varsome lists several
neighboring variants classified as pathogenic in ClinVar, in-
cluding an adjacent p.(Phe4808Asn) variant (also caused by a
dinucleotide substitution: chr19:39070679-TT>AA).
Additionally, chr19:39070676-A>T, p.(Asn4807Tyr), and
chr19-39070677:A>G, p.(Asn4807Ser) variants, located in
the position of our dinucleotide variant and listed in dbSNP
are both predicted to be damaging and are very rare in
gnomAD Exomes. The TTN p.(Cys30071Arg) variant
(NM_001256850.1), also described as p.(Cys31712Arg)
(NM_001267550.2), has been previously shown to be dam-
aging and causative [23, 24].
Immunohistochemistry
Immunofluorescence staining for lamin A/C revealed normal
labeling of the nuclear envelope in proband of Family 1 as
well as in controls (Fig. S4).
Discussion
This study provides evidence that (1) p.(Arg89Cys) LMNA
mutation causes a myopathy featuring PAM pathology, (2)
RYR1 mutations may be an additional cause of autosomal
dominant PAM with an unusual phenotype of tibial myopa-
thy, and (3) the p.(Cys30071Arg) mutation in TTN gene re-
sponsible for hereditary myopathy with early respiratory fea-
tures (HMERF) is associated with cardiac involvement.
Fig. 4 Muscle biopsy findings
from proband of Family 3.
Muscle fibers with amorphous
material that stains eosinophilic
on H&E (a) and dark blue on GT
(b). Images were obtained with
obj × 20
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Lamins are intermediate filament proteins that constitute
the nuclear lamina, a structure that underlies and provides
mechanical support to inner nuclear membrane [25, 26].
Beside the structural role, nuclear lamins are involved in chro-
matin organization and transcription regulation as well as in
physical connection between the nucleus and the cytoskeleton
[25, 26]. LMNA encodes for lamin A and lamin C that results
from alternative splicing of exon 10; lamins A and C are
expressed in most differentiated cells [25, 26]. Despite muta-
tions in LMNA have been associated with a heterogeneous
group of diseases, known as the “laminopathies,” four main
clinical phenotypes affecting skeletal and cardiac muscle have
been reported including limb-girdle muscular dystrophy type
1B (LGMD1B), the Emery-Dreifuss muscular dystrophy
Table 1 Candidate causative























(PM2, PP3, PP5, BP1)
II-3 (A) +
II-1 (A) +
A, affected; U, unaffected; DP, patient affected by myopathy with divergent phenotype
*Verdict and identified ACMG criteria are based on the Varsome database; PS/PM/PP, pathogenic strong/mod-
erate/supporting; BS/BP, benign strong, supporting
Fig. 5 Candidate causative variants detected in three families. The Sanger sequencing peaks and Integrative Genomics Viewer screenshots are provided
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(EDMD), congenital muscular dystrophy (MDCL), and dilat-
ed cardiomyopathy [25, 26]. Proband of Family 1 and her
daughter harbored the same p.(Arg89Cys) mutation in
LMNA. Themutationwas previously reported in a patient with
EDMD who had a different clinical phenotype and without
pathological description [22]. Both members of our family
clinically presented with arrhythmogenic cardiomyopathy
and developed a proximal limb muscle weakness only in
adulthood while in EDMD patient clinical disease onset was
in early childhood with selective muscle involvement of the
lower limbs and elbows contractures, cardiac conduction de-
fects occurred at a later age. There was also no evidence of
joint contractures in the mother and her daughter. MFM pa-
thology has been reported in patients with LMNA myopathy
but the occurrence is extremely rare and never associated with
the described mutation [27, 28]. Interestingly, the brother of
the proband who had a late-onset limb-girdle clinical pheno-
type was found to not carry the LMNA variant suggesting a
mutation in a different gene or a sporadic or acquired myop-
athy. In addition, the patient did not develop an early arrhyth-
mia unlike the proband and her daughter.
The RYR1 gene encodes the skeletal muscle ryanodine re-
ceptor, a calcium channel that resides in the junctional sarco-
plasmic reticulum (SR) membrane and, by interacting with the
dihydropyridine receptor located on the T-tubules, releases
calcium from the SR to the sarcoplasm in response to an action
potential, triggeringmuscle contraction [29]. Autosomal dom-
inant mutations in RYR1 have been classically reported in
patients with susceptibility to malignant hyperthermia (MH)
and congenital central core disease (CCD) [30, 31]. Other
RYR1-related phenotypes with both autosomal dominant
and recessive inheritance pattern include multiminicore dis-
ease (MnD), centronuclear myopathy (CNM), congenital fiber
type disproportion (CFTD), and King-Denborough syndrome
(KDS) [30, 31]. Proband of family 2 was found to carry het-
erozygous missensemutation p.(Asn4807Phe) inRYR1, a var-
iation which maps to the C-terminal MH3 domain of the pro-
tein. Several lines of evidence suggest that the RYR1 variant
identified in our patient is disease-causing; the variant was
previously reported in a patient with CCD [32], it occurred
at highly conserved positions, and it is predicted to have a
damaging effect. Unfortunately, segregation analysis could
not be performed because the proband’s father was dead and
his old mother lived in a different region of the country. The
onset and distribution of muscle weakness in our patient in-
volving only distal lower limbs in the fourth decade of life is
quite different from that observed in individual patients carry-
ing the same RYR1 variant [32] or the adjacent
p.(Phe4808Asn) mutation [33–35] in which muscle weakness
was proximal starting during early childhood [32, 34, 35] or
there was only a susceptibility to MH without clinical myop-
athy [33]. In addition, he had a relevant cardiac history with
atrial fibrillation which required ablation. Despite RYR1
expression in cardiac muscle is limited, recently rare patients
with cardiac involvement have been described [30].
Finally, we studied an Italian family and found the pre-
viously reported p.(Cys30071Arg) mutation in the TTN
gene [23, 24]. TTN encodes the giant protein titin which
spans through half of the sarcomere, with N- and C-
terminal regions located at the Z-disk and M-line, respec-
tively, and which is involved in thick filaments assembling
and stabilization [36]. Titin sequence is characterized by
fibronectin type III (FN3) and immunoglobulin-like mod-
ules that are repeated and organized in complex sequence
arrangements [36]. The missense p.(Cys30071Arg) muta-
tion occurs in exon 343 encoding for the FN3 domain 119
of the titin A-band, a region of the protein that establishes
strong interactions with the thick filaments providing a
molecular template for their assembling and represents
the most common mutation in patients with HMERF, re-
ported in more than 20 families [23, 24, 37–41]. The clin-
ical manifestations and the histological features described
in our family are consistent with HMERF phenotype, in-
cluding autosomal dominant inheritance, adult onset,
weakness in proximal, distal and respiratory muscles, and
MFM pathology [23, 24, 37–41]. The significant involve-
ment of cardiac muscle in our patients represents a new
aspect of the disease. The proband died suddenly and car-
diac investigations documented severe sinus tachycardia;
furthermore, his sister developed heart conduction defects
including several episodes of supraventricular paroxysmal
tachycardia. HMERF does not appear to be associated with
major cardiac involvement [42] but our observations sug-
gest that cardiac surveillance should be recommended in
patients carrying this mutation.
Additionally, we identified multiple VUS in other genes
linked or not with myopathy besides the potentially causative
mutations (Table S1). Novel variants inDCTN1,MYH14, and
RBM20 were identified in Family 1 with cardiac and limb-
girdle muscle involvement and in TRIM63, ACTC1, and
TTN in the proband of family 2 with a distal lower limb phe-
notype and atrial fibrillation. Clinical significance of these
additional variants remains speculative and needs to be eluci-
dated; theymight contribute to the variability of the phenotype
due to a synergistic or an antagonistic effect [43].
Alternatively, it has been suggested that the cumulative bur-
den of variants might affect the functioning of target tissue
modulating the penetrance and/or the expression of clinical
phenotype [5].
In summary, whole-exome analysis in our PAM patients
identified novel variants in known disease genes, a novel can-
didate disease gene, and documented phenotypic expansion
for known causative genes.
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